Controlled release of corticosteroid with biodegradable nanoparticles for treating experimental autoimmune uveitis
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Noninfectious uveitis is a potentially blinding ocular condition that often requires treatment with corticosteroids to prevent inflammation‐related ocular complications. Severe forms of uveitis such as panuveitis that affects the whole eye often require a combination of topical and either regional or systemic corticosteroid. Regional corticosteroids are currently delivered inside the eye by intravitreal injection (e.g. Ozurdex®, an intravitreal dexamethasone implant). Intravitreal injection is associated with rare but potentially serious side effects, including endophthalmitis, retinal and vitreous hemorrhage, and retinal detachment. Subconjunctival (SCT) injection is a less invasive option that is a common route used for post‐surgical drug administration and treatment of infection and severe inflammation. However, it is the water soluble form of dexamethasone, dexamethasone sodium phosphate (DSP), that has been demonstrated to achieve high intraocular penetration with subconjunctival injection. It is difficult to load highly water soluble drugs, such as DSP, and achieve sustained drug release using conventional encapsulation methods. We found that use of carboxyl‐terminated poly(lactic‐co‐glycolic acid) (PLGA) allowed encapsulation of DSP into biodegradable nanoparticles (NP) with relatively high drug content (6% w/w) if divalent zinc ions were used as an ionic “bridge” between the PLGA and DSP. DSP‐Zn‐NP had an average diameter of 210nm, narrow particle size distribution (polydispersity index ˜0.1), and near neutral surface charge (−9mV). DSP‐Zn‐NP administered by SCT injection provided detectable DSP levels in both the anterior chamber and vitreous chamber of the eye for at least 3weeks. In a rat model of experimental autoimmune uveitis (EAU), inflammation was significantly reduced in both the front and back of the eye in animals that received a single SCT injection of DSP‐Zn‐NP as compared to animals that received either aqueous DSP solution or phosphate buffered saline (PBS). DSP‐Zn‐NP efficacy was evidenced by a reduced clinical disease score, decreased expression of various inflammatory cytokines, and preserved retinal structure and function. Furthermore, SCT DSP‐Zn‐NP significantly reduced microglia cell density in the retina, a hallmark of EAU in rats. DSP‐Zn‐NP hold promise as a new strategy to treat noninfectious uveitis and potentially other ocular inflammatory disorders. HIGHLIGHTSNanoparticles provide sustained release steroid treatment for autoimmune uveitis.Water‐soluble dexamethasone is more effective for subconjunctival injection.Method for improving loading and sustained release of water‐soluble dexamethasone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coutinho, A. E., & Chapman, K. E. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.04.005 · Cited by 1,815
Gaudana, R., Ananthula, H. K., Parenky, A., & Mitra, A. K. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9183-3 · Cited by 1,406 · cited 2×
“Water-soluble small molecules typically show much higher trans-scleral drug penetration than hydrophobic drugs, perhaps due to the higher concentration gradients possible with more water-soluble molecules [10,45].”
Challenges and obstacles of ocular pharmacokinetics and drug delivery
Urtti, A. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.07.027 · Cited by 1,003
Cited by
Huang, Y., Guo, X., Wu, Y., Chen, X., Feng, L., Xie, N., & Shen, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01745-z · Cited by 490
Nanoparticles: Taking a Unique Position in Medicine
Joseph, T., Kar Mahapatra, D., Esmaeili, A., Piszczyk, Ł., Hasanin, M., Kattali, M., Haponiuk, J., & Thomas, S. (2023) · Nanomaterials · doi:10.3390/nano13030574 · Cited by 480
Han, H., Li, S., Xu, M., Zhong, Y., Fan, W., Xu, J., Zhou, T., Ji, J., Ye, J., & Yao, K. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114770 · Cited by 322
Hyaluronic acid in ocular drug delivery
Zhang, X., Wei, D., Xu, Y., & Zhu, Q. (2021) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2021.118006 · Cited by 196
Lipid nanoparticles for the posterior eye segment
Bonilla, L., Espina, M., Severino, P., Cano, A., Ettcheto, M., Camins, A., García, M. L., Souto, E. B., & Sánchez-López, E. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics14010090 · Cited by 76
Metadata
- Authors
- Luo, L., Yang, J., Oh, Y., Hartsock, M. J., Xia, S., Kim, Y.-C., Ding, Z., Meng, T., Eberhart, C. G., Ensign, L. M., Thorne, J. E., Stark, W. J., Duh, E. J., Xu, Q., & Hanes, J.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2019-02
- Volume
- 296
- Pages
- 68-80
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2910202648
- Cited by
- 79
- References
- 3
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Controlled release of corticosteroid with biodegradable nanoparticles for treating experimental autoimmune uveitis. https://app.cochat.ai/papers/10.1016/j.jconrel.2019.01.018
- The paper
- Luo, L., Yang, J., Oh, Y., Hartsock, M. J., Xia, S., Kim, Y.-C., Ding, Z., Meng, T., Eberhart, C. G., Ensign, L. M., Thorne, J. E., Stark, W. J., Duh, E. J., Xu, Q., & Hanes, J. (2019). Controlled release of corticosteroid with biodegradable nanoparticles for treating experimental autoimmune uveitis. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2019.01.018
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.